Thomas Krausgruber receives the Karl Landsteiner Award for Immunological Basic Research of the Austrian Society for Allergology and Immunology (ÖGAI, www.oegai.org) handed over at the Virtual Congress Day December 4th 2020.
Thomas Krausgruber from Christoph Bock’s lab was selected by the Award Committee of the ÖGAI supported by international reviewers for his work and widely recognized publication in Nature entitled ‘Structural cells are key regulators of organ-specific immune responses’ (https://www.nature.com/articles/s41586-020-2424-4).
Thomas is supported by the FWF and contributed with his research critically to research area 3 “homeostatic regulation”. The entire team of the SFB congratulates to this award, which is endowed with 4,000 € by the Karl Landsteiner & Eisler-Terramare Foundation – Memorial Private Foundation.
Heidi Neubauer advances to principal investigator in second funding period.
Heidi has been a post-doctoral fellow with Richard Moriggl and made significant contributions during the first stage of the SFB to elucidating the structural and functional consequences of oncogenic driver mutations in STAT3 and 5.
She recently became principal investigator within the ERA-NET PerMed funded project “JAKSTAT-Target”, which includes partners from Helsinki (Satu Mustjoki, Tero Aittokallio), Cologne (Marco Herling) and Toronto (Patrick Gunning, Benjamin Haibe-Kains). Within the international consortium Heidi will contribute work on preclinical models to investigate the role of the JAK-STAT pathway in mature T cell lymphomas and to identify potential drugs and drug synergies targeting this pathway. Heidi received her PhD at the University of Adelaide (AUS) and accepted a postdoctoral position at the Ludwig Boltzmann Institute of Cancer Research Vienna (AT). Since 2019 Heidi is employed as an assistant professor at the University of Veterinary Medicine Vienna. Based on her successful work under the mentorship of Richard Moriggl, for the second funding period Heidi has taken over as group leader in the SFB and guides the research on STAT5 changes the chromatin landscape during malignant T-cell transformation and on critical cooperativity partners of STAT5 in neoplastic T cells as novel therapeutic targets.